摘要
目的探讨阿昔洛韦联合脾氨肽治疗儿童传染性单核细胞增多症的疗效及其对EB病毒特异性抗体的作用。方法选取2015年1月—2017年12月收治的儿童传染性单核细胞增多症患者60例,将患者随机分为治疗组和对照组,每组30例。治疗组采用阿昔洛韦和脾氨肽联合治疗,对照组仅使用阿昔洛韦治疗。治疗4周后,观察两组患者疗效以及EB病毒特异性抗体水平。结果治疗组的总治愈率显著高于对照组(P=0.04),两组患者出现不良反应情况之间的差异不存在统计学意义(P>0.05);治疗组EB病毒特异性抗体和EB病毒核抗原阳性数量少于对照组,差异具有统计学意义(P<0.05)。结论阿昔洛韦联合脾氨肽治疗儿童传染性单核细胞增多症的疗效显著,可提高EB病毒特异性抗体的阴转率,值得在临床推广。
Objective To explore the efficacy of acyclovir combined with splenaminopeptide on the treatment of pediatric infectious mononucleosis and their effect on specific antibodies of EB virus.Methods Totally,60 patients with pediatric infectious mononucleosis admitted to our hospital from January 2015 to December 2017 were selected and randomly assigned into the treatment group and the control group,with 30 cases in each group.The treatment group was treated with acyclovir and splenaminopeptide,while the control group were only intervened with acyclovir.After 4 weeks of treatment,efficacy of medications and the level of specific antibodies of EB virus in the two groups were determined.Results The total cure rate of the treatment group was higher than that of the control group(P=0.04).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).The number of specific antibodies of EB virus and positive nuclear antigen of EB virus in the treatment group was significantly smaller than that in the control group(P<0.05).Conclusion Acyclovir combined with splenic Aminopeptide is significantly effective in the treatment of pediatric infectious mononucleosis,for it can enhance the negative conversion rate of specific antibodies of EB virus.Therefore,it is worthy of promotion in clinical practice.
作者
黄东辉
郭瑜
蔡伟霞
HUANG Donghui;GUO Yu;CAI Weixia(Qiaotou Hospital of Dongguan City,Dongguan 523520,China)
出处
《现代医院》
2018年第3期426-428,共3页
Modern Hospitals
基金
东莞市社会科技发展项目(201650715001167)
